This morning, Insys Therapeutics, Inc. (NASDAQ:INSY) announced that the company has added four pharmaceutical industry veterans to its leadership team.
These new hires come at a pivotal time at Insys as the company faces continued controversy and investigation regarding its Subsys (fentanyl spray) and as they prepare to launch their Syndros (dronabinol oral solution) after receiving label approval from the FDA at the end of May.
Joining Insys are:
Brian Jennings, Vice President of Sales
Mr. Jennings joins Insys from Purdue Pharma where he was the Regional Business Director of Sales. He has more than 25 years of experience in the pharmaceutical industry and previously held positions at Publicis Healthcare Group, Sanofi, Roche U.S. (Genentech), Unimed, and Searle to name a few.
Dr. Dean Mariano, Senior Director, Clinical Development/Medical Affairs
Dr. Dean Mariano is a practicing physician that is focused on pain management. He has lectured extensively across the country on the topic of safe opioid prescribing. Dr. Mariano is a Diplomat of the American Board of Anesthesiology, holds a subspecialty certification in Pain Medicine and is an Assistant Professor at Quinnipiac University's Frank H. Netter, M.D. School of Medicine.
Ariyapadi (Krishna) Krishnaraj, Vice President of Marketing and Managed Care
Ariyapadi Krishnaraj has more than 30 years of pharmaceutical industry experience. He previously served at the Vice President of Marketing at Novartis where he led that company's efforts to launch innovative programs with pharmacies and develop global pricing policies for vaccines. He also worked as an Executive Director for GlaxoSmithKline where he developed patient educational campaigns and participated in multiple successful product launches.
Scott Warlick, General Manager, Manufacturing
Mr. Warlick has more than 25 years of experience in pharmaceutical and specialty chemical manufacturing. He joins Insys from Mylan Laboratories where he worked as a Senior Director of Manufacturing.
Insys' President and Chief Executive Officer, Saeed Motahari had this to say about the new hires:
“These key hires both elevate and diversify the talent within this growing organization. We are delighted to welcome Brian, Dean, Krishna and Scott to the Company. Each of these executives brings highly relevant experience to Insys, and we look forward to their contributions as we execute our mission of improving the quality of care for patients in need.”
For more information on Insys Therapeutics Inc., be sure to check out the company's marijuana stock profile in our biotech marijuana stock database. For a comprehensive list of all marijuana stocks, be sure to check out our complete marijuana stock database. Also, don't forget that because Insys Therapeutics is listed on the NASDAQ, shares can be traded for free using the Robinhood app.
Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana update. Also, don't forget to connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram if you haven't already.
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.